Desirudin

At a glance

Overview

Desirudin is related to the anticoagulant protein hirudin and was developed for surgical thrombosis prevention. Its clinical program demonstrated efficacy against postoperative deep-vein thrombosis, including events detected on scheduled venography. The US indication was specifically prophylaxis in elective hip replacement rather than treatment of all established thromboembolism. Iprivask’s FDA Purple Book record now lists discontinued marketing status, so historical efficacy should not be presented as current routine availability. It also differs from bivalirudin, another hirudin-related direct thrombin inhibitor, in molecule, duration, route, and labeled setting. The drugs cannot be substituted simply because both inhibit thrombin.

Supporting sources [1] [2] [3]

How it works

Desirudin binds both the active site and a fibrin-recognition region of thrombin, preventing conversion of fibrinogen to fibrin and other thrombin-mediated coagulation actions. Its activity does not require antithrombin. Renal clearance is clinically important, and accumulation can intensify anticoagulation. Direct thrombin inhibition explains both postoperative thrombosis prevention and the potential for serious bleeding, particularly around invasive or neuraxial procedures.

Supporting sources [1] [2] [3]

What the hip-replacement studies measured

A randomized study found fewer venographically detected deep-vein thromboses with desirudin than with unfractionated heparin after total hip replacement. This supports its historical prophylactic indication. Scheduled imaging detects events that may not be symptomatic, so trial endpoints should be described accurately rather than equated with a proven mortality reduction.

Supporting sources [1] [2]

Bleeding around surgery and spinal procedures

The historical label carries a boxed warning about spinal or epidural hematomas that can lead to permanent paralysis when anticoagulation overlaps neuraxial anesthesia or puncture. Active bleeding and hypersensitivity to hirudins are contraindications. Other drugs affecting hemostasis can further increase bleeding risk.

Supporting sources [1]

Kidney function changes exposure

Desirudin requires particular attention to renal impairment because reduced clearance can prolong anticoagulation. The historical label describes renal adjustments and coagulation monitoring in relevant patients. Its pharmacology differs from short-acting procedural agents, so a general class label cannot replace product-specific perioperative planning.

Supporting sources [1]

Is Iprivask currently marketed in the US?

FDA’s Purple Book identifies Iprivask with discontinued marketing status. This is important for a current knowledge base: an old label documents an approved indication and safety history, but does not demonstrate that the product is available through routine contemporary supply. Country-specific availability must be checked separately.

Supporting sources [3]

Is desirudin the same as other direct thrombin inhibitors?

No. Desirudin shares a target with other anticoagulants, but its structure, approved surgical setting, renal handling and evidence are distinct. Product-specific instructions and current availability matter. Similar names or mechanisms do not justify substituting another medicine or assuming an identical balance of bleeding and clot-prevention effects.

Supporting sources [1] [2]